论文部分内容阅读
目的研究长期应用rhCNTF对谷氨酸钠(MSG)肥胖大鼠血脂的影响。方法建立MSG肥胖大鼠模型。3月龄时将肥胖动物随机分5组:分别皮下注射rhCNTF300μg·kg-1·d-1(高剂量组)、100μg·kg-1·d-1(中剂量组)、30μg·kg-1·d-1(低剂量组);西布曲明灌胃8 mg·kg-1·d-1(阳性对照组);模型组和对照组均给予生理盐水1 mL·kg-1·d-1,连续给药33 d。末次给药后24 h,同时动物禁食过夜后,在水合氯醛麻醉下测体重、身长,计算LI;断头后取腹部脂肪称重计算脂肪系数;腹主动脉取血离心后测血清总胆固醇、甘油三酯、高密度脂蛋白、血糖和血清胰岛素水平。结果(1)造模:正常大鼠189.40±38.72 g,谷氨酸钠肥胖大鼠平均体重(246.72±36.67)g,(P<0.001);LI(Lee’s指数)分别为289.27±9.05和304.42±9.64(P<0.001),说明造模成功。(2)药物实验结果高、中剂量给药组LI、脂肪系数、血总胆固醇、甘油三酯、血糖明显下降,高剂量组胰岛素水平也有所下降,达到统计学要求的显著性。结论rhCNTF30～300μg·kg-1·d-1皮下注射连续用药33 d,对谷氨酸钠肥胖大鼠具有明显的降脂作用,可能对Ⅱ型糖尿病肥胖有效。
Objective To investigate the effect of long-term rhCNTF treatment on serum lipids in rats with glutamate (MSG) obesity. Methods MSG obese rat model was established. At 3 months of age, the obese animals were randomly divided into 5 groups: subcutaneous injection of rhCNTF 300 μg · kg -1 · d -1 (high dose), 100 μg · kg -1 · d -1 (middle dose), 30 μg · kg -1 · D-1 (low-dose group); sibutramine gavage 8 mg · kg-1 · d-1 (positive control group); model group and control group were given normal saline 1 mL · kg-1 · d- 1, continuous administration of 33 d. At 24 h after the last administration, the animals were fasted for overnight, and their body weight and length were measured under chloral hydrate anesthesia. The lipids were calculated by weighing the abdomen fat after decapitation and the sera Cholesterol, triglycerides, HDL, blood glucose and serum insulin levels. RESULTS: The average body weight was 189.40 ± 38.72 g in normal rats and 246.72 ± 36.67 g in obese rats with glutamate (P <0.001), and LI (Lee’s index) was 289.27 ± 9.05 and 304.42 ± 9.64 (P <0.001), indicating successful modeling. (2) The results of the drug experiment LI, fat coefficient, blood total cholesterol, triglyceride, blood glucose decreased significantly in high and medium dose administration groups, insulin level in high dose group also decreased, reaching statistical significance. CONCLUSION: Subcutaneous administration of 30 ~ 300μg · kg-1 · d-1 rhCNTF for 33 days can significantly reduce lipid levels in rats with glutamate-induced obesity and may be effective in obesity in type Ⅱ diabetes.